Strive Compounding Pharmacy alleges the two pharma companies are coordinating an effort to restrict compounded access.

Immunocore is expanding its ImmTAX platform into autoimmune disease, outlining plans to start first‑in‑human trials of ...

The arrival of oral Wegovy across 70,000 US pharmacies offers a more affordable and convenient weight-loss treatment option ...

AstraZeneca has agreed to buy AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

Despite lacklustre dealmaking, there were still trends identified from company presentations, such as pharma's upcoming ...

Despite a lacklustre FDI environment in British life sciences, the pharma industry could be set for a period of renaissance amid US trade agreements.

Novartis has announced that the FDA has granted a breakthrough therapy designation to ianalumab, a treatment for Sjögren’s ...

Atea showcased its Phase III HCV programme at JPM, positioning the regimen for test-and-treat adoption in 1,800 patients.

Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its ...

InterAx Biotech has entered into a strategic research collaboration and licensing agreement with Alveus Therapeutics to ...

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

The most notable strategic choice is prioritising myasthenia gravis (MG) and Sjögren's disease as lead indications while ...